Oncology News

VIENNA — A new study presented at the 2015 International Liver Congress showed that cancer rates were higher in patients with hepatitis C virus infection vs. those without the infection, according to an analysis of the Kaiser Permanente Southern California cancer registry.

Individuals who are overweight or obese are at increased risk for liver cancer, but those who consume coffee have a decreased risk, according to a Continuous Update Project report on liver cancer published by the World Cancer Research Fund.

Nexavar monotherapy prolonged survival in patients with hepatocellular carcinoma with extrahepatic spread who achieved disease control, according to findings published in the Journal of Hepatology.

VIENNA — A new algorithm accurately predicted hepatocellular carcinoma among a cohort of patients with cirrhosis, according to a study presented at the 2015 International Liver Congress.

VIENNA — As non-alcoholic fatty liver disease reaches ‘epidemic’ status, its relation to hepatocellular carcinoma is also on the rise with a higher rate of mortality among those patients with fatty liver-related carcinoma, according to a study presented at the 2015 International Liver Congress.

VIENNA — A number of patients with alcohol-related cirrhosis developed hepatocellular carcinoma and other complications over time, regardless of alcohol and tobacco consumption, according to data presented at the 2015 International Liver Congress.

VIENNA — Clinicians stopped a trial of novel tyrosine kinase inhibitor TSU-68 in hepatocellular carcinoma after the drug failed to best placebo in overall survival in patients with hepatocellular carcinoma, according to findings presented at the 2015 International Liver Congress.

VIENNA — Exome sequencing of liver tumors was found to be effective in determining relationships between environmental exposures and mutation signatures, which may assist in determining therapy for patients with hepatocellular carcinoma in the future, according to data presented at a press conference at the 2015 International Liver Congress.

Can-Fite BioPharma Ltd. has submitted an application to the European Medicines Agency for orphan drug designation of CF102 for the treatment of hepatocellular carcinoma, according to a press release from the manufacturer.

SillaJen, Inc. has reached an agreement with the FDA on a Special Protocol Assessment for a phase 3 clinical trial of its drug Pexa-Vec for the treatment of advanced liver cancer and will begin enrolling patients later this year, according to a press release.